Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 267
- 主要终点
- Number of Subjects Who Completed Treatment.
研究概览
简要总结
Adherence to the prescribed treatment regimen with PegIntron and Rebetol affects the chance of achieving a sustained virologic response in patients with hepatitis C. The objective of this study is to evaluate the proportion of patients who complete treatment with PegIntron pen and Rebetol while participating in a patient assistance program. The patient assistance program can consist of prophylactic treatment (eg, with growth factors, psychiatric medications) or other interventions (eg, psychotherapy, patient support groups, visiting nurse, nurse telephone calls, educational literature).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treatment-naïve patients with hepatitis C
- •Patients treated with PegIntron pen and Rebetol
- •Patients receiving patient assistance program
排除标准
- •Not applicable
研究组 & 干预措施
All Treated Patients
All patients participating in the study
干预措施: PegIntron pen (peginterferon alfa-2b; SCH 54031) (Biological)
All Treated Patients
All patients participating in the study
干预措施: Rebetol (ribavirin; SCH 18908) (Drug)
结局指标
主要结局
Number of Subjects Who Completed Treatment.
时间窗: Assessed at the end of the 48-week treatment.
次要结局
- Average Length of Treatment.(Assessed at the end of treatment. The prescribed treatment duration was 48 weeks.)